Cell & Gene Therapy Bioanalytical Testing Services Market Size Worth US$ 950.06 Million by 2032 | CAGR: 7.3%

The cell & gene therapy bioanalytical testing services market size is expected to reach USD 950.06 million by 2032, according to a new study by Polaris Market Research. The report “Cell & Gene Therapy Bioanalytical Testing Services Market Share, Size, Trends, Industry Analysis Report – By Test Type (Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, and Others), By Product Type, By Stage of Development, By Indication, and By Region; Segment Forecast, 2023–2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing number of studies revealing the ability of cell and gene therapies to treat multiple diseases is driving investments in research activities in the healthcare industry. The government funding to increase its capacity to test medication and healthcare equipment in the marketplace. For instance, in March 2023, the UK government announced a grant of USD 10 million for the National Health Service Blood and Transplant (NHSBT) to open a new facility called the Clinical Biotechnology Centre (CBC) for the development and manufacturing of new cell and gene therapies. Furthermore, the growing number of cancer cases across the world is significantly emphasizing countries to invest in cell and gene therapy research. The most populous nations, such as India and China, are launching new therapies for the cancer treatment. For instance, in April 2024, Tata Memorial Centre & Indian Institute of Technology (IIT), Bombay launched India’s first developed CAR-T cell therapy for cancer treatment. Thus new cell therapy is boosting demand for cell & gene therapy bioanalytical testing services, which is contributing to market growth.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/cell-and-gene-therapy-bioanalytical-testing-services-market/request-for-sample

The rising pharmaceutical companies' initiatives to increase investments in the design and production of cell and gene therapies are driving the demand for performance-evaluating tools and services, which is positively influencing the global market. For instance, in February 2024, Azzur Group announced the new offering of analytical laboratory testing services as a part of developing cell and gene therapy. This is specifically to test advanced therapeutics and other medical products. The increasing prevalence of chronic diseases is encouraging researchers to innovate effective medications. The growing development of cell and gene therapies effectively performs in treating health issues among the population. According to the Food and Drug Administration (FDA), ∼100,000 people are suffering from sickle cell disease. This contributed to the design of new therapies around the world. In December 2023, the US FDA announced approval for two gene therapies—Lyfgenia &  Casgevy—for the treatment of sickle cell disease.

Cell & Gene Therapy Bioanalytical Testing Services Market Report Highlights

• The bioavailability & bioequivalence studies segment, by test type is anticipated to witness the highest growth rate during the forecast period due to rising drug innovation activities.
• In terms of product type, the cell therapy segment accounted for the largest market share in 2023, owing to the increasing production of cell therapies for several diseases.
• APAC is projected to register the highest growth during the forecast period, attributable to the growing investments in the biotechnological industry.
• Europe is expected to register a significant CAGR in the cell & gene therapy bioanalytical testing services market during the forecast period due to due increased investment in advanced therapeutic research.
• BioAgilytix Labs, Charles River Laboratories, Intertek Group, IQVIA, KCAS Bioanalytical Services, and Pharmaron are among the global market players.

Polaris Market Research has segmented the cell & gene therapy bioanalytical testing services market report on the basis of test type, product type, stage of development, indication, and region:

By Test Type Outlook (Revenue – USD million, 2019–2032)

• Bioavailability & Bioequivalence Studies
• Pharmacokinetics
• Pharmacodynamics
• Others

By Product Type Outlook (Revenue – USD million, 2019–2032)

• Gene Therapy
• Gene-Modified Cell Therapy
• Cell Therapy

By Stage of Development Outlook (Revenue – USD million, 2019–2032)

• Nonclinical
• Clinical

By Indication Outlook (Revenue – USD million, 2019–2032)

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Others

By Regional Outlook (Revenue – USD million, 2019–2032)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
• Latin America
  • Argentina
  • Brazil
  • Mexico
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Cell & Gene Therapy Bioanalytical Testing Services Market Report Scope